How does mismatch repair deficiency affect Prostate Cancer treatment

Mismatch Repair Deficiency in Prostate Cancer: What You Need to Know

What is Mismatch Repair Deficiency?

Mismatch repair (MMR) is a cellular "spell-check" system that catches and fixes errors when DNA is copied. When this system doesn't work properly—called mismatch repair deficiency (dMMR) or microsatellite instability (MSI)—errors accumulate in cancer cells' DNA. This actually creates an important opportunity for treatment.

How This Affects Treatment Decisions

The Clinical Reasoning: Oncologists have discovered that cancers with mismatch repair deficiency have a distinctive characteristic: they develop a very high number of mutations. This mutation burden (sometimes called "tumor mutational burden" or TMB) makes these cancers potentially vulnerable to a specific class of drugs called immunotherapy.

Here's why: The high mutation load means cancer cells display many abnormal proteins on their surface. This makes them easier for the immune system to recognize and attack—like putting a bright target on the cancer cells.

Treatment Approaches for MMR-Deficient Prostate Cancer

General Treatment Landscape: According to NCCN Guidelines for Prostate Cancer, immunotherapy drugs called checkpoint inhibitors (such as pembrolizumab) have shown promise in MMR-deficient cancers across multiple cancer types. For prostate cancer specifically, these approaches are being studied and may be considered in certain clinical contexts, particularly for:

• Advanced or metastatic disease
• Cancers that have progressed despite other treatments
• Patients whose tumors show high microsatellite instability

Why This Matters: Traditional prostate cancer treatments (hormone therapy, chemotherapy, radiation) work differently than immunotherapy. If your cancer has MMR deficiency, your oncologist may have additional options to discuss beyond the standard approaches.

Questions to Ask Your Oncology Team

Since mismatch repair status is an important biomarker, here are specific questions to guide your conversation:

1. "Has my tumor been tested for mismatch repair deficiency or microsatellite instability? If not, would this testing be helpful for my case?"

2. "Given my specific diagnosis and stage, what are ALL the treatment options available to me, including immunotherapy approaches?"

3. "If I do have MMR deficiency, are there clinical trials testing immunotherapy that I might be eligible for?"

4. "What are the potential benefits and side effects of immunotherapy compared to other treatment options for my situation?"

5. "How will we monitor whether treatment is working, and what's the plan if one approach isn't effective?"

Important Context

According to NCCN Prostate Cancer Guidelines, mismatch repair testing is increasingly recommended for advanced prostate cancers, as it can identify patients who may benefit from targeted immunotherapy approaches. However, the specific role of immunotherapy in prostate cancer continues to evolve, and your oncologist will determine what's most appropriate based on your complete clinical picture—including your cancer stage, grade, prior treatments, and overall health.

The presence of MMR deficiency doesn't automatically mean immunotherapy is the right choice; rather, it's one important piece of information your care team uses to personalize your treatment plan.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.